Literature DB >> 28930444

Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms.

Maha S Al-Keilani1, Nour A Al-Sawalha1.   

Abstract

Despite the advancement in cancer therapy, a high number of patients fail treatment because of drug resistance. Several preclinical in vitro data suggest that phenylbutyrate has antiproliferative, antiangiogenic, antimetastatic, immunomodulatory, and differentiating properties. Moreover, phenylbutyrate administration in vivo provided an oncoprotective effect. However, the results of clinical trials indicate that the antineoplastic potential of phenylbutyrate is hindered by its pharmacokinetic and pharmacodynamic properties. Thus, understanding the exact mechanisms of the anticancer effect of phenylbutyrate could assist in the selection of patients who will best benefit from this drug. The present review discusses the proposed mechanisms of antineoplastic effect of phenylbutyrate and the preclinical and clinical evidence suggesting its potential role as anticancer in different types of cancer.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28930444     DOI: 10.1021/acs.chemrestox.7b00149

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  5 in total

1.  NMR Metabolomics Protocols for Drug Discovery.

Authors:  Fatema Bhinderwala; Robert Powers
Journal:  Methods Mol Biol       Date:  2019

Review 2.  The role of protein acetylation in carcinogenesis and targeted drug discovery.

Authors:  Jingru Yang; Cong Song; Xianquan Zhan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-12       Impact factor: 6.055

Review 3.  Dairy consumption and hepatocellular carcinoma risk.

Authors:  Bodo C Melnik
Journal:  Ann Transl Med       Date:  2021-04

4.  Metabolite Profiling in Anticancer Drug Development: A Systematic Review.

Authors:  Nadda Muhamad; Kesara Na-Bangchang
Journal:  Drug Des Devel Ther       Date:  2020-04-09       Impact factor: 4.162

5.  The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells.

Authors:  Maha S Al-Keilani; Karem H Alzoubi; Saied A Jaradat
Journal:  Clin Pharmacol       Date:  2018-10-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.